|
EP1664006A2
(en)
|
2003-09-06 |
2006-06-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
DE602004022319D1
(de)
*
|
2003-11-14 |
2009-09-10 |
Vertex Pharma |
Thiazole udn oxazole als modulatoren von atp-bindungs-kassetten-transportern
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
WO2006002421A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
EP1912983B1
(en)
|
2005-08-11 |
2011-06-08 |
Vertex Pharmaceuticals, Inc. |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
SI1945632T1
(sl)
|
2005-11-08 |
2014-03-31 |
Vertex Pharmaceuticals Incorporated |
Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
|
|
CA2635760C
(en)
|
2005-12-28 |
2014-07-15 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
AU2006332726B2
(en)
|
2005-12-28 |
2012-12-13 |
Vertex Pharmaceuticals Incorporated. |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
MX2008012945A
(es)
|
2006-04-07 |
2009-01-15 |
Vertex Pharma |
Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
NZ581259A
(en)
|
2007-05-09 |
2012-07-27 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP2187884B1
(en)
*
|
2007-08-24 |
2016-03-30 |
Vertex Pharmaceuticals Incorporated |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
|
AU2008298545B2
(en)
*
|
2007-09-14 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
PT2217572E
(pt)
|
2007-11-16 |
2014-02-17 |
Vertex Pharma |
Moduladores de isoquinolina de transportadores de cassete de ligação a atp
|
|
SI2639224T1
(sl)
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
AU2008333845C1
(en)
|
2007-12-07 |
2014-01-16 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
|
CN101998854A
(zh)
*
|
2007-12-07 |
2011-03-30 |
沃泰克斯药物股份有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂
|
|
AU2008335031B2
(en)
|
2007-12-13 |
2013-11-28 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
CN102245573B
(zh)
|
2008-02-28 |
2013-11-20 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
|
WO2009123896A1
(en)
|
2008-03-31 |
2009-10-08 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as cftr modulators
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
RU2011117177A
(ru)
|
2008-09-29 |
2012-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
ДОЗИРОВАННЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ 3-(6-(1-(2,2-ДИФТОРБЕНЗО[d][1,3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ
|
|
CA2741718A1
(en)
*
|
2008-10-23 |
2010-04-29 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
JP5699090B2
(ja)
|
2008-12-30 |
2015-04-08 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
|
|
AU2010226400B2
(en)
|
2009-03-20 |
2016-07-14 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
LT3150198T
(lt)
|
2010-04-07 |
2021-12-10 |
Vertex Pharmaceuticals Incorporated |
3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
|
|
ME02446B
(me)
|
2010-04-07 |
2016-09-20 |
Vertex Pharma |
Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
|
|
MX342288B
(es)
|
2010-04-22 |
2016-09-23 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
CA2852991C
(en)
|
2011-11-08 |
2019-12-31 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
CA2865519C
(en)
|
2012-02-27 |
2018-01-02 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US9012496B2
(en)
|
2012-07-16 |
2015-04-21 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
|
|
BR112015028173A2
(pt)
|
2013-05-10 |
2017-07-25 |
Nimbus Apollo Inc |
inibidores de acc e usos dos mesmos
|
|
JP6417403B2
(ja)
|
2013-05-10 |
2018-11-07 |
ギリアド アポロ， エルエルシー |
Ａｃｃ阻害剤及びその使用
|
|
EP2994138A4
(en)
*
|
2013-05-10 |
2016-12-28 |
Nimbus Apollo Inc |
ACC-HEMMER AND USES THEREOF
|
|
EP2994139B1
(en)
|
2013-05-10 |
2019-04-10 |
Gilead Apollo, LLC |
Acc inhibitors and uses thereof
|
|
BR112016010403A2
(pt)
|
2013-11-12 |
2017-08-08 |
Vertex Pharma |
Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
|
|
KR102447581B1
(ko)
|
2014-04-15 |
2022-09-28 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
|
|
WO2015186063A1
(en)
*
|
2014-06-03 |
2015-12-10 |
Novartis Ag |
Naphthyridinedione derivatives
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
US9567322B2
(en)
|
2014-10-31 |
2017-02-14 |
Abbvie S.Á.R.L. |
Substituted tetrahydropyrans and method of use
|
|
CA2968130C
(en)
|
2014-11-18 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
|
US10047051B2
(en)
|
2015-06-02 |
2018-08-14 |
Abbvie S.Á.R.L. |
Substituted pyridines and method of use
|
|
US9840513B2
(en)
*
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
JP6779992B2
(ja)
|
2015-10-09 |
2020-11-04 |
アッヴィ・エス・ア・エール・エル |
Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
|
|
BR112018007145A2
(pt)
|
2015-10-09 |
2018-11-06 |
AbbVie S.à.r.l. |
ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
|
|
CA3000802A1
(en)
|
2015-10-09 |
2017-04-13 |
Abbvie S.A.R.L. |
Compounds for treatment of cystic fibrosis
|
|
BR112018072047A2
(pt)
|
2016-04-26 |
2019-02-12 |
AbbVie S.à.r.l. |
moduladores da proteína reguladora de condutância transmembranar de fibrose cística
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
WO2018116185A1
(en)
|
2016-12-20 |
2018-06-28 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
EP3747882A1
(en)
|
2019-06-03 |
2020-12-09 |
AbbVie Overseas S.à r.l. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
US11236067B2
(en)
|
2019-07-12 |
2022-02-01 |
Orphomed, Inc. |
Compound for treating cystic fibrosis
|
|
EP4031592B1
(en)
|
2019-09-20 |
2025-04-30 |
SABIC Global Technologies B.V. |
Compounds for use in catalyst compositions for the production of polyolefins
|
|
AU2020382827A1
(en)
|
2019-11-12 |
2022-05-26 |
Genzyme Corporation |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US20220213041A1
(en)
|
2021-01-06 |
2022-07-07 |
AbbVie Global Enterprises Ltd. |
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
|
|
US20220211692A1
(en)
|
2021-01-06 |
2022-07-07 |
AbbVie Global Enterprises Ltd. |
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
|
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
JP2024533216A
(ja)
|
2021-09-03 |
2024-09-12 |
ジェンザイム・コーポレーション |
インドール化合物及び使用方法
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
CN120584119A
(zh)
|
2022-09-07 |
2025-09-02 |
希安纳医疗公司 |
化合物、组合物及其使用方法
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|